Minerva Neurosciences Reports Second Quarter 2015 Financial Results and Business Updates

Opening of clinical sites in six countries builds momentum in MIN-101 Phase IIb schizophrenia trial First patient dosed in Phase IIa study with MIN-117 in major depressive disorder First patient dosed in Phase Ib study with MIN-202 as adjunctive treatment for major depressive disorder; MIN-202 data in insomnia presented at SLEEP meeting Company adds to Board and management Management to host conference call today at 8:30 a.m...

New York, 05/08/2015 (informazione.news - comunicati stampa - varie)

WALTHAM, Mass., Aug. 5, 2015 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system (CNS) disorders, today reported key business updates and financial results for the second quarter ended June 30, 2015.

"Measurable progress has been made in the initiation of clinical sites and enrollment for our Phase IIb trial with MIN-101 in schizophrenia and in the dosing of our first patient in the Phase IIa trial with MIN-117 for major depressive disorder," said Dr. Remy Luthringer, president and chief executive officer of Minerva. "In addition, Janssen Pharmaceutica NV, our development partner, has dosed the first patient in a Phase Ib trial of MIN-202 (JNJ-42847922) as an adjunctive treatment for major depressive disorder and is planning to begin a Phase IIa trial in insomnia disorder under our co-development and license agreement.

"We believe that we are now well positioned to achieve our objectives through mid-2016, including data readouts from our most advanced programs, MIN-101 and MIN-117, which will represent significant steps to meeting unmet patient needs in CNS conditions," said Dr. Luthringer.

Minerva Neurosciences will host a conference call and live audio webcast today at 8:30 a.m. Eastern Time to discuss the quarter and recent business activities. To participate, please dial (877) 312-5845 (domestic) or (765) 507-2618 (international) and refer to conference ID 76101573.

The live webcast can be accessed under "Events and Presentations" in the Investors and Media section of Minerva's website at ir.minervaneurosciences.com . The archived webcast will be available on the website beginning approximately two hours after the event for 90 days.

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of products to treat CNS diseases. Minerva's proprietary compounds include: MIN-101, in development for the treatment of schizophrenia; MIN-202 (JNJ-42847922), in development for the treatment of insomnia; MIN-117, in development for the treatment of major depressive disorder; and MIN-301, in development for the treatment of Parkinson's disease. Minerva's common stock is listed on the NASDAQ Global Market under the symbol "NERV." For more information, please visit www.minervaneurosciences.com . 

www.minervaneurosciences.com

 

CONTACT: William B. Boni

         VP, Investor Relations/

         Corp. Communications

         Minerva Neurosciences, Inc.

         (617) 600-7376

 

 

 

Copyright GlobeNewswire


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: %s via Globenewswire